VeracyteVCYT
Recorded

Veracyte 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Kelly Gura, Director of Investor Relations.

Kelly GuraDirector of Investor Relations

Please go ahead. Good afternoon, everyone, and thank you for joining us today to review Veracyte's third quarter 2026 financial results.

Kelly GuraDirector of Investor Relations

Joining me on the call are Marc Stapley, our Chief Executive Officer, and Rebecca Chambers, our Chief Financial Officer. Dr. John Leite, our Chief Commercial Officer, will also be available for Q&A. Earlier this afternoon, we issued a press release detailing our third quarter financial results, and we posted an accompanying presentation in the investor section of our website. Before we begin, I would like to remind you that statements we make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance that they will prove to be correct. The company undertakes no obligation to update any forward-looking statements except as required by law.

Kelly GuraDirector of Investor Relations

To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including the most recent Forms 10-Q and 10-K. In addition, this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included in today's earnings release accessible from the investors section of Veracyte's website. I will now turn the call over to Marc Stapley, Veracyte's CEO.

Marc StapleyCEO

Thank you, Kelly, and thank you all for joining us today. Third quarter revenue increased approximately 15% year-over-year to $151.8 million, and we delivered another quarter of strong profitability and cash generation. Afirma exceeded expectations, while Decipher Prostate volume was lower than we expected. Today, I will share our observations regarding these trends, the steps we are taking to support future growth, and why we remain confident in the long-term opportunity for all of our tests. First, I would like to highlight some of the exciting momentum we are seeing across our portfolio. We have made good progress advancing our breast and bladder strategies over the last few months with the launches of Prosigna LDT for breast cancer and TrueMRD for muscle-invasive bladder cancer, or MIBC.

Marc StapleyCEO

In September, we strengthened our urology portfolio through the acquisition of Convergent Genomics, adding a urine-based technology platform that complements our tissue and blood-based capabilities across the bladder cancer continuum. We also advanced our market access strategies in breast, prostate, and bladder cancer, helping preserve and expand access to our valuable tests for Medicare-eligible patients. Now I will walk through our performance across each of our growth drivers. Starting with Decipher Prostate, we delivered nearly 30,000 tests in the third quarter, representing 12% year-over-year growth, with volume approximately 1,000 tests lower than we expected. We are disappointed by that shortfall, but believe we have identified the underlying drivers and are taking action to address them. Firstly, we now believe that the higher favorable guideline updates developed by NCCN for the 2023 and 2024 practice guidelines drove a temporal acceleration in physician adoption, resulting in two years of outsized growth.

Marc StapleyCEO

Physicians who began or increased ordering following those updates remain engaged, and their order volumes are still growing. However, we believe that growth is now normalizing. Secondly, as discussed last quarter, the 2026 NCCN low-risk guideline change impacting genetic classifiers and MMAI tests, as well as a shift to more low-risk patients choosing active surveillance without undergoing further testing, has moderated growth in that setting to single digits. Thirdly, novel technologies such as digital pathology have drawn attention as physicians consider how to incorporate those tools into their patient care pathways alongside the Decipher test. This requires our commercial team to spend more time discussing the clinical utility of molecular information, the strength and differentiation of Decipher's broad evidence base, and the complementarity of digital pathology and AI-based tools, taking time away from core selling.

Marc StapleyCEO

To address this, as well as our expanding portfolio of urology products, we are taking a multi-pronged approach, beginning with greater investment in the channel. Rather than our typical handful of sales hires annually, we plan to expand the urology team by approximately 30% next year across field representatives, medical science liaisons, and sales leadership. This will enable our representatives to focus on core selling while continuing to grow the commercial channel to deliver high-value transcriptome and MRD testing with Decipher Bladder, TrueMRD, and over time, UroAmp. We are also expanding our efforts to generate and articulate new predictive and prognostic claims for Decipher, as well as other important tumor molecular features. Decipher is the most widely validated test in prostate cancer, with growing evidence for broader uses in both localized and metastatic disease as care standards and treatments evolve.

Marc StapleyCEO

We will strengthen our evidence generation flywheel by adding additional bioinformatic capabilities to capture real-world evidence of Decipher's benefit and support analysis of key ongoing clinical studies. While we believe these investments will support broader adoption and deeper utilization, helping sustain Decipher's growth, given the factors mentioned, we are resetting our incremental annual volume growth expectations to 12,000-15,000 tests, with the low end as a reasonable floor for now. Several catalysts could help us reach or exceed the high end of this range, including new predictive evidence further validating Decipher's use across the cancer continuum, key phase III trial readouts spanning all risk categories, and continued evolution of our offering with new molecular and digital pathology insights to help inform patient care. We have advanced these catalysts, generating three new predictive claims in recent months.

Marc StapleyCEO

At ASTRO, an analysis from the phase III NRG/RTOG 0815 trial provided new predictive evidence for Decipher in intermediate-risk prostate cancer, the largest market segment, where treatment intensity remains uncertain. The data shows that Decipher can help identify patients more likely to benefit from the addition of short-term hormone therapy to radiation, extending its evidence in this setting from prognosis to prediction. Last week at the ESMO World Congress, new predictive evidence from the phase III STAMPEDE trial further expanded Decipher's evidence in clinically very high-risk, node-negative non-metastatic disease, demonstrating the test's ability to help identify which patients may benefit most from adding abiraterone to standard hormone therapy. This builds on Decipher's well-established role in high and very high-risk prostate cancer, including prior STAMPEDE prognostic data that were recently incorporated in the NCCN 2027 Prostate Cancer Guidelines for the first time.

Marc StapleyCEO

Earlier this summer at ASCO, data from the ENZAMET trial provided predictive evidence for Decipher in metastatic hormone-sensitive prostate cancer. Continued investment in new claims is essential to build evidence across the risk continuum. Potential catalysts, if positive, include readouts from the prospective NCI-sponsored phase III GUIDANCE and PREDICT-RT randomized trials, which are now fully enrolled. They are evaluating treatment intensification and de-intensification in intermediate and high-risk disease, respectively, using Decipher as an integral biomarker to determine eligibility or treatment assignment. As discussed last quarter, phase III low-risk studies, including Jenny Space and G-MAJOR, are evaluating Decipher's role in active surveillance decisions and could begin reporting preliminary findings as early as next year.

Marc StapleyCEO

Finally, one of our key differentiators is the combination of GRID and our collaborations with the academic community, which enables us to continually expand the insights we can deliver to physicians as prostate care becomes increasingly complex. We are bringing clinically validated signatures, including PORTOS, P10, and PAM50, into our molecular features report to provide additional insights. DPAI represents another opportunity to build on this strategy by bringing molecular and digital pathology insights together to better inform prostate cancer care. We expect our first publication on our DPAI algorithm in the next few quarters, building on the data presented at ASCO GU last year and fueling further research in this important area. We believe this will lead to multiple publications supporting the complementary use of DPAI alongside molecular testing in settings where it can add clinical value to the Decipher result.

Marc StapleyCEO

In summary, our confidence in Decipher's long-term opportunity is unchanged. The franchise is growing across all risk categories, gaining share and penetration, with ongoing prospective studies designed to generate level 1 evidence across low, intermediate, high risk, and metastatic disease. Notably, many of these trials were started more than a decade ago and are anticipated to read out over the next few years, efforts that, to our knowledge, have not been replicated. As evidence standards rise, we believe this depth and breadth will further differentiate Decipher, expand adoption and utilization, and help address the approximately 334,000 men diagnosed annually in the U.S. We continue to view 80% market share and 80% penetration as appropriate, achievable long-term targets, supported by Decipher's differentiating evidence base and expanding evidence pipeline. Turning now to Afirma. We delivered another exceptionally strong quarter, driven by approximately 19,000 tests, 12% year-over-year, fueled by deeper utilization among existing physicians and continued share gains.

Marc StapleyCEO

With the strongest sequential Q3 volume increase since 2020, this performance underscores our data-driven evidence generation approach and our leadership in thyroid nodule molecular diagnostics. Further, our V2 transcriptome workflow significantly reduced the no-result rate, helping more patients receive results and contributing approximately 300 basis points to year-over-year volume growth this quarter. We increasingly use the Afirma GRID to support academic and industry collaborations that could yield new signatures, molecular insights, and use cases, fueling further publications and presentations that expand Afirma's evidence base. At this week's American Thyroid Association, or ATA, annual meeting, Afirma will be featured in no less than 10 posters and abstracts, including two oral presentations, our strongest podium presence in recent years.

Marc StapleyCEO

The studies build on Afirma's established diagnostic role and explore how gene expression data can illuminate cancer risk and biology. We are very pleased with Afirma's year-to-date performance and believe share gains, market growth, and deeper penetration position the franchise for continued growth in 2027 and beyond, supported by ongoing clinical evidence. Moving on to Prosigna. We launched the test in the U.S. a few months ago following the prospective phase III OPTIMA readout, which provided practice-changing level 1A evidence for treatment decisions. Prosigna identified more than two-thirds of clinically high-risk women who could safely avoid chemotherapy, one of the most consequential decisions in early-stage breast cancer. OPTIMA builds on an already substantial body of evidence, including 157 publications to date featuring Prosigna, and more than 1,200 featuring the PAM50 classifier on which the test is built.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day